Literature DB >> 31645456

A green tea-triggered genetic control system for treating diabetes in mice and monkeys.

Jianli Yin1, Linfeng Yang1, Lisha Mou2, Kaili Dong1, Jian Jiang1, Shuai Xue1, Ying Xu1, Xinyi Wang1, Ying Lu2, Haifeng Ye3.   

Abstract

Cell-based therapies are recognized as the next frontier in medicine, but the translation of many promising technologies into the clinic is currently limited by a lack of remote-control inducers that are safe and can be tightly regulated. Here, we developed therapeutically active engineered cells regulated by a control system that is responsive to protocatechuic acid (PCA), a metabolite found in green tea. We constructed multiple genetic control technologies that could toggle a PCA-responsive ON/OFF switch based on a transcriptional repressor from Streptomyces coelicolor We demonstrated that PCA-controlled switches can be used for guide RNA expression-mediated control of the CRISPR-Cas9 systems for gene editing and epigenetic remodeling. We showed how these technologies could be used as implantable biocomputers in live mice to perform complex logic computations that integrated signals from multiple food metabolites. Last, we used our system to treat type 1 and type 2 diabetes in mice and cynomolgus monkeys. This biocompatible and versatile food phenolic acid-controlled transgenic device opens opportunities for dynamic interventions in gene- and cell-based precision medicine.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2019        PMID: 31645456     DOI: 10.1126/scitranslmed.aav8826

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  15 in total

1.  Genetic-code-expanded cell-based therapy for treating diabetes in mice.

Authors:  Chao Chen; Guiling Yu; Yujia Huang; Wenhui Cheng; Yuxuan Li; Yi Sun; Haifeng Ye; Tao Liu
Journal:  Nat Chem Biol       Date:  2021-11-15       Impact factor: 15.040

2.  Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control.

Authors:  Guiling Yu; Mingliang Zhang; Ling Gao; Yang Zhou; Longliang Qiao; Jianli Yin; Yiwen Wang; Jian Zhou; Haifeng Ye
Journal:  Mol Ther       Date:  2021-09-14       Impact factor: 11.454

3.  A versatile genetic control system in mammalian cells and mice responsive to clinically licensed sodium ferulate.

Authors:  Yidan Wang; Shuyong Liao; Ningzi Guan; Yuanxiao Liu; Kaili Dong; Wilfried Weber; Haifeng Ye
Journal:  Sci Adv       Date:  2020-08-07       Impact factor: 14.136

4.  Small-molecule inducible transcriptional control in mammalian cells.

Authors:  Aarti Doshi; Fatemeh Sadeghi; Navin Varadarajan; Patrick C Cirino
Journal:  Crit Rev Biotechnol       Date:  2020-08-30       Impact factor: 8.429

5.  Engineering Mammalian Cells to Control Glucose Homeostasis.

Authors:  Jiawei Shao; Xinyuan Qiu; Mingqi Xie
Journal:  Methods Mol Biol       Date:  2021

6.  A small and highly sensitive red/far-red optogenetic switch for applications in mammals.

Authors:  Yang Zhou; Deqiang Kong; Xinyi Wang; Guiling Yu; Xin Wu; Ningzi Guan; Wilfried Weber; Haifeng Ye
Journal:  Nat Biotechnol       Date:  2021-10-04       Impact factor: 54.908

7.  A non-invasive far-red light-induced split-Cre recombinase system for controllable genome engineering in mice.

Authors:  Jiali Wu; Meiyan Wang; Xueping Yang; Chengwei Yi; Jian Jiang; Yuanhuan Yu; Haifeng Ye
Journal:  Nat Commun       Date:  2020-07-24       Impact factor: 14.919

8.  A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice.

Authors:  Ting Li; Xianjun Chen; Yajie Qian; Jiawei Shao; Xie Li; Shuning Liu; Linyong Zhu; Yuzheng Zhao; Haifeng Ye; Yi Yang
Journal:  Nat Commun       Date:  2021-01-27       Impact factor: 14.919

Review 9.  Engineering precision therapies: lessons and motivations from the clinic.

Authors:  Mingqi Xie; Mirta Viviani; Martin Fussenegger
Journal:  Synth Biol (Oxf)       Date:  2020-11-24

10.  A far-red light-inducible CRISPR-Cas12a platform for remote-controlled genome editing and gene activation.

Authors:  Xinyi Wang; Kaili Dong; Deqiang Kong; Yang Zhou; Jianli Yin; Fengfeng Cai; Meiyan Wang; Haifeng Ye
Journal:  Sci Adv       Date:  2021-12-10       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.